<DOC>
	<DOCNO>NCT02147210</DOCNO>
	<brief_summary>The principal purpose study regulation expression ephrin-B1 immunofluorescence kidney biopsy patient Chronic transplant glomerulopathy ( CTG ) compare biopsy prior CTG , patient . Level fluorescence CTG biopsy experimental reference value .</brief_summary>
	<brief_title>Chronic Transplant Glomerulopathy Regulation Expression Ephrin B1</brief_title>
	<detailed_description>Chronic transplant glomerulopathy ( CTG ) specific lesion kidney transplantation poor prognostic factor affect transplant survival . Diagnosis remain microscopic lesion irreversible . Recent study prove strong correlation CTG antibody mediate rejection ( AMR ) possible link chronic aggression endothelial cell . However , unknown reason , AMR lead CTG . Our recent data mice demonstrate ephrin-B1 express glomerular endothelial cell knockout mouse gene encode ephrin-B1 develop progressively ultrastructural glomerular lesion close modification observe CTG , well proteinuria chronic renal failure , suggest ephrin B1 could participate CTG . Moreover , preliminary study human kidney transplant biopsy observe decrease ephrin-B1 immunofluorescence glomerulus CTG , even low grade . These data , ultrastructural modification Knock Out ( KO ) mouse suggest early regulation kidney expression ephrin-B1 glomerulus may occur process lead CTG antibody-mediated kidney rejection ( AMR ) . The purpose study determinate ephrin-B1 expression modify CTG .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Kidney transplant patient renal biopsy store `` collection University Hospital Toulouse '' ( collection NÂ° DC2009989 ) receive information purpose study , use biopsy manifest opposition . Kidney transplant patient iterative biopsy least : postsurgery biopsy D0 ( early posttransplant biopsy D7 least one biopsy protocol . Age &gt; 18 year Case group : Kidney transplant patient , follow `` organ transplant unity '' CHU Toulouse , antecedent CMR progress CTG 2006 2013 . Control group : Kidney transplant patient , follow `` organ transplant unity '' CHU Toulouse , antecedent CMR without progress CTG 2006 2013 patient uncontrolled hypertension patient diabetes mellitus patient treat treated mTOR inhibitor recurrence initial glomerular pathology de novo glomerulopathy patient include another study exclusion period still go</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic transplant glomerulopathy</keyword>
	<keyword>antibody mediate rejection</keyword>
	<keyword>Ephrin-B1</keyword>
</DOC>